We are seeking a highly motivated and creative scientist with expertise in the cell engineering and gene editing space, to help us advance our universal iPSC-derived allogeneic cell products for targeting hematological and solid tumors. He/she will be responsible for utilizing existing cell engineering methodologies, as well as developing and incorporating novel tools for targeted gene editing in iPSCs in support of cell therapy efforts. The ideal candidate will successfully work closely with research colleagues and collaborate with external partners and functional teams to achieve our collective corporate goals.
Experience in gene editing and cell engineering is absolutely essential
Responsibilities: • Gene editing at target gene loci using CRISPR-Cas9 and Cas12a in iPSCs • Targeted gene insertions using Homology Directed Repair (HDR) and optimizing gene knock-in, knock-out (KIKO) systems in iPSCs • Application of dsDNA break-free genome editing including base editing and rAAV-mediated HDR • Working closely with the Bioinformatics group to characterize off-target effects post-gene editing using GUIDE-seq, CIRCLE-seq or other relevant approaches • Cloning constructs into expression vectors • Possess the ability to independently propose, design, execute and report research projects
Qualifications: • Experience in genome editing using DNA base editing is highly desirable • Extensive cell culture experience essential; culturing and differentiation of iPSCs to immune effector cells desirable • Multi-color flow cytometry and cell sorting experience essential • Proficiency in molecular biology techniques including molecular cloning, qPCR and familiar with DNA analysis software including Vector NTI
Requirements: • PhD in biological sciences, with 4 years of professional experience • Proven expertise in genome editing technologies including CRISPR-Cas9, CRISPR-Cpf1 • Ability to perform in a fast-paced environment and handle multiple priorities simultaneously • Outstanding collaborative and communication skills
About Century Therapeutics, LLC:
Century Therapeutics is developing novel allogeneic living cell products for oncology that overcome the limitations of first-generation cell therapies. Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophages) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care. https://www.centurytx.com/